NYSE:PKI Revvity (PKI) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$115.24▼$137.1152-Week Range N/AVolume1.63 million shsAverage Volume851,117 shsMarket Capitalization$14.57 billionP/E Ratio15.01Dividend Yield0.24%Price Target$54.00 Stock AnalysisStock Analysis Get Revvity alerts: Email Address Revvity MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside∞ Upside$54.00 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainability-1.99Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings Growth17.71%From $4.97 to $5.85 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.17 out of 5 starsMedical Sector139th out of 910 stocksAnalytical Instruments Industry6th out of 26 stocks 3.5 Analyst's Opinion Consensus RatingRevvity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRevvity has received no research coverage in the past 90 days.Read more about Revvity's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PKI. Previous Next 1.7 Dividend Strength Dividend YieldRevvity has a dividend yield of 0.24%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthRevvity does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Revvity is 3.65%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Revvity will have a dividend payout ratio of 4.79% next year. This indicates that Revvity will be able to sustain or increase its dividend.Read more about Revvity's dividend. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevvity has received a 40.52% net impact score from Upright. PerkinElmer seems to create the most significant positive value in categories "Taxes", "Jobs", and "Creating knowledge". The positive contribution in the "Creating knowledge" impact category is mostly driven by its "Clinical research services", "Laboratory reagents", and "Centrifuges" products. See details.Environmental SustainabilityThe Environmental Impact score for Revvity is -1.99. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 4 people have searched for PKI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revvity insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.52% of the stock of Revvity is held by insiders.Percentage Held by Institutions85.22% of the stock of Revvity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Revvity's insider trading history. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Revvity are expected to grow by 17.71% in the coming year, from $4.97 to $5.85 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revvity is 15.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Revvity is 15.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 112.46.Price to Earnings Growth RatioRevvity has a PEG Ratio of 0.50. PEG Ratios below 1 indicate that a company could be undervalued. Previous Next See Top Rated MarketRank™ Stocks Here Ad Mode MobilePre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.Claim Exclusive 100% Bonus: $0.25/Share About Revvity Stock (NYSE:PKI)Revvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.Read More Ad Mode MobilePre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.Claim Exclusive 100% Bonus: $0.25/Share PKI Stock News HeadlinesJuly 19, 2024 | finance.yahoo.comRevvity, Inc. (RVTY)February 13, 2024 | morningstar.comRevvity Inc PKISeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.December 1, 2023 | businesswire.comRevvity Launches EONIS Q System Enabling Faster, Simplified Newborn Screening for SMA and SCIDNovember 1, 2023 | benzinga.comRevvity Stock (NYSE:RVTY), Analyst Ratings, Price Targets, PredictionsOctober 29, 2023 | finance.yahoo.comRevvity, Inc. and Element Biosciences, Inc. Pioneer Next-Generation Sequencing Kits Market with Innovative Genomic Analysis SolutionsAugust 2, 2023 | finance.yahoo.comRevvity (RVTY) Beats on Q2 Earnings, Lowers '23 EPS ViewAugust 1, 2023 | fool.comRevvity (NYSE: PKI)September 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.July 31, 2023 | finance.yahoo.comRevvity (RVTY) to Report Q2 Earnings: What's in the Cards?May 19, 2023 | finance.yahoo.comPerkinElmer Completes Transformation to Become RevvityMay 18, 2023 | finance.yahoo.comRevvity Announces New License Agreement for Next-Generation Base Editing TechnologyMay 16, 2023 | markets.businessinsider.comJ.P. Morgan Keeps Their Hold Rating on PerkinElmer (PKI)May 15, 2023 | msn.comCitigroup Maintains Revvity (PKI) Buy RecommendationMay 15, 2023 | markets.businessinsider.comAnalyst Ratings for RevvityMay 15, 2023 | markets.businessinsider.comPerkinElmer (PKI) Receives a Buy from CitigroupMay 13, 2023 | msn.comBarclays Maintains Perkinelmer (PKI) Equal-Weight RecommendationMay 12, 2023 | msn.comStifel Maintains Perkinelmer (PKI) Hold RecommendationSee More Headlines Receive PKI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revvity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/11/2023Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:PKI CUSIP71404610 CIK31791 Webwww.perkinelmer.com Phone(781) 663-6900Fax781-663-5985Employees16,700Year Founded1937Price Target and Rating Average Stock Price Target$54.00 High Stock Price Target$54.00 Low Stock Price Target$54.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$7.68 Trailing P/E Ratio15.01 Forward P/E RatioN/A P/E Growth0.5Net Income$569.18 million Net Margins28.94% Pretax Margin13.81% Return on Equity11.17% Return on Assets5.83% Debt Debt-to-Equity Ratio0.48 Current Ratio2.43 Quick Ratio2.15 Sales & Book Value Annual Sales$3.31 billion Price / Sales0.00 Cash FlowN/A Price / Cash Flow9.88 Book Value$58.49 per share Price / BookN/AMiscellaneous Outstanding Shares126,410,000Free Float125,755,000Market Cap$14.57 billion OptionableOptionable Beta1.10 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesPrahlad Ramadhar SinghPresident, Chief Executive Officer & DirectorTajinder S. VohraSenior Vice President-Global OperationsMaxwell KrakowiakChief Financial Officer & Senior Vice PresidentYi Ping LinChief Quality, Regulatory & Clinical OfficerJayashree Kailas ThackerChief Information Officer & Senior Vice PresidentKey CompetitorsAgilent TechnologiesNYSE:AMettler-Toledo InternationalNYSE:MTDIlluminaNASDAQ:ILMNWatersNYSE:WATBio-TechneNASDAQ:TECHView All Competitors PKI Stock Analysis - Frequently Asked Questions How were Revvity's earnings last quarter? Revvity, Inc. (NYSE:PKI) posted its quarterly earnings data on Thursday, May, 11th. The medical research company reported $1.01 EPS for the quarter, missing the consensus estimate of $1.07 by $0.06. The medical research company earned $674.87 million during the quarter, compared to analyst estimates of $686.30 million. Revvity had a net margin of 28.94% and a trailing twelve-month return on equity of 11.17%. Is Revvity doing a stock buyback? Revvity's board initiated a share repurchase program on Thursday, May 11th 2023, which permits the company to buy back $600,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 4.1% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board of directors believes its stock is undervalued. What is Prahlad Singh's approval rating as Revvity's CEO? 27 employees have rated Revvity Chief Executive Officer Prahlad Singh on Glassdoor.com. Prahlad Singh has an approval rating of 79% among the company's employees. Does Revvity have any subsidiaries? Revvity subsidiaries include BioLegend, Immunodiagnostic Systems, Nexcelom Bioscience, SIRION Biotech, Oxford Immunotec, Horizon Discovery, Cisbio.com, and more. What other stocks do shareholders of Revvity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Revvity investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), Home Depot (HD) and Bristol-Myers Squibb (BMY). This page (NYSE:PKI) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revvity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revvity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.